Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Anta Sports Expands Global Footprint With Strategic Puma Stake 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
NEW ORLEANS, Dec. 23, 2016 -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until January 9, 2017 to file lead plaintiff applications in a securities class action lawsuit against Impax Laboratories Inc. (Nasdaq:IPXL), if they purchased the Company’s securities between February 20, 2014 through November 3, 2016, inclusive (the “Class Period”). This action is pending in the United States District Court for the Districts of New Jersey and California.
What You May Do
If you purchased securities of Impax and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, call toll-free at 1-877-515-1850 or email KSF Managing Partner Lewis Kahn ([email protected]). If you wish to serve as a lead plaintiff in this class action, you must petition the Court by January 9, 2017.
About the Lawsuit
Impax and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On November 3, 2016, Bloomberg reported that an “antitrust investigation by the Justice Department, begun about two years ago, now spans more than a dozen companies,” including Impax, “and about two dozen drugs.” The article further stated that a “grand jury probe is examining whether some executives agreed with one another to raise prices, and the first charges could emerge by the end of the year.” Additionally, according to Bloomberg, “[g]eneric drug companies are also contending with a civil price-fixing investigation by [the] Connecticut Attorney General.”
About Kahn Swick & Foti, LLC
KSF, whose partners include the Former Louisiana Attorney General Charles C. Foti, Jr., is a law firm focused on securities, antitrust and consumer class actions, along with merger & acquisition and breach of fiduciary litigation against publicly traded companies on behalf of shareholders. The firm has offices in New York, California and Louisiana.
To learn more about KSF, you may visit www.ksfcounsel.com.
Contact: Kahn Swick & Foti, LLC Lewis Kahn, Managing Partner [email protected] 1-877-515-1850 206 Covington St. Madisonville, LA 70447
